Ciarán Martin Fitzpatrick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ciarán Martin Fitzpatrick has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Ulrik Gether
University of Copenhagen
6 shared publications - David Paul Drucker Woldbye
Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark
5 shared publications - Jesper Tobias Andreasen
Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark
5 shared publications - Andreas Toft Soerensen
Molecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark
4 shared publications Jesper T. Andreasen
Department of Drug Design and Pharmacology , University of Copenhagen , Copenhagen 2100 , Denmark
4 shared publications- Maitane Caballero-Puntiverio
Dept. of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen, Denmark; Symptoms Biology, H. Lundbeck A/S, Ottiliavej 9, 2500, Valby, Denmark
3 shared publications
Latest Publications
- Open Access
- 31 May 2023
- Published by Springer Nature in BMC Rheumatology
- Vol. 7 (1) , 1-4
Patient and public involvement in rheumatic and musculoskeletal research: an idea whose time has firmly come
Patient and public involvement is an idea whose time has firmly come. It is the views of these Guest Editors that it is the right thing to do morally and improves research quality and applicability.
- 31 May 2023
- Published by Springer Nature in BMC Rheumatology
- Vol. 7 (1) , 1-4
Open AccessPatient and public involvement in rheumatic and musculoskeletal research: an idea whose time has firmly come
Patient and public involvement is an idea whose time has firmly come. It is the views of these Guest Editors that it is the right thing to do morally and improves research quality and applicability.
- 27 January 2022
- Published by Taylor & Francis in Journal of Psychoactive Drugs
- Vol. 54 (4) , 324-327
Comment and Response: (Lugo-Radillo & Cortez-Lopez, 2020) Long-Term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-Containing Mushrooms
Editor’s NoteThe Journal of Psychoactive Drugs published a case study reporting reduction of obsessive-compulsive disorder (OCD) symptoms after consumption of psilocybin-containing mushrooms (Lugo-...
- 27 January 2022
- Published by Taylor & Francis in Journal of Psychoactive Drugs
- Vol. 54 (4) , 324-327
Comment and Response: (Lugo-Radillo & Cortez-Lopez, 2020) Long-Term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-Containing Mushrooms
Editor’s NoteThe Journal of Psychoactive Drugs published a case study reporting reduction of obsessive-compulsive disorder (OCD) symptoms after consumption of psilocybin-containing mushrooms (Lugo-...
- Open Access
- 23 June 2021
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 18 (8) , 542
Social disparities in COVID-19 prevention
Patients with cardiovascular disease who live with socioeconomic disadvantage face barriers to healthy living. A new study assessing social disadvantage burden reveals that this patient population has poor adherence to COVID-19 risk-mitigation recommendations.
- 23 June 2021
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 18 (8) , 542
Open AccessSocial disparities in COVID-19 prevention
Patients with cardiovascular disease who live with socioeconomic disadvantage face barriers to healthy living. A new study assessing social disadvantage burden reveals that this patient population has poor adherence to COVID-19 risk-mitigation recommendations.
- 1 February 2021
- Published by Elsevier in Neuropharmacology
- Vol. 183, 107838
The 5-hydroxytryptamine 2A receptor agonists DOI and 25CN-NBOH decrease marble burying and reverse 8-OH-DPAT-induced deficit in spontaneous alternation
- 1 February 2021
- Published by Elsevier in Neuropharmacology
- Vol. 183, 107838
The 5-hydroxytryptamine 2A receptor agonists DOI and 25CN-NBOH decrease marble burying and reverse 8-OH-DPAT-induced deficit in spontaneous alternation
- 6 June 2019
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 10 (7) , 3094-3100
8-OH-DPAT Induces Compulsive-like Deficit in Spontaneous Alternation Behavior: Reversal by MDMA but Not Citalopram
Rodents exhibit natural exploratory behaviors, which can be measured by the spontaneous alternation behavior (SAB) test. Perseverance in this test induced by the 5-hydroxytrypamine 1A receptor (5-HT1AR) agonist, 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT), resembles compulsive behaviors observed in humans and manifests as reduced alternation ratio. This study characterized 8-OH-DPAT-induced perseverance in the SAB test in C57BL/6JOlaHsd male mice by co-administration of WAY100635, citalopram and the 5-HT releasing agent 3,4-methylenedioxymethamphetamine (MDMA) to deepen the understanding of 5-HT-dependent mechanisms. The 5-HT1AR mechanism of 8-OH-DPAT (1.0 mg/kg, p<0.01) on perseverance was confirmed by co-administration of the 5-HT1AR antagonist WAY100635 (2.0 mg/kg, p<0.05), which attenuated the effects of 8-OH-DPAT. Such effects could also be reversed by MDMA (1.0 mg/kg, p<0.05; 10.0 mg/kg, p<0.001) but not citalopram. These findings confirm the importance of 5-HT in regulating perseverative behavior. Future investigations are required to determine the predictive validity of the 8-OH-DPAT-disrupted SAB as an inducible mouse model of compulsivity.
- 6 June 2019
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 10 (7) , 3094-3100
8-OH-DPAT Induces Compulsive-like Deficit in Spontaneous Alternation Behavior: Reversal by MDMA but Not Citalopram
Rodents exhibit natural exploratory behaviors, which can be measured by the spontaneous alternation behavior (SAB) test. Perseverance in this test induced by the 5-hydroxytrypamine 1A receptor (5-HT1AR) agonist, 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT), resembles compulsive behaviors observed in humans and manifests as reduced alternation ratio. This study characterized 8-OH-DPAT-induced perseverance in the SAB test in C57BL/6JOlaHsd male mice by co-administration of WAY100635, citalopram and the 5-HT releasing agent 3,4-methylenedioxymethamphetamine (MDMA) to deepen the understanding of 5-HT-dependent mechanisms. The 5-HT1AR mechanism of 8-OH-DPAT (1.0 mg/kg, p<0.01) on perseverance was confirmed by co-administration of the 5-HT1AR antagonist WAY100635 (2.0 mg/kg, p<0.05), which attenuated the effects of 8-OH-DPAT. Such effects could also be reversed by MDMA (1.0 mg/kg, p<0.05; 10.0 mg/kg, p<0.001) but not citalopram. These findings confirm the importance of 5-HT in regulating perseverative behavior. Future investigations are required to determine the predictive validity of the 8-OH-DPAT-disrupted SAB as an inducible mouse model of compulsivity.
- 1 April 2019
- Published by Elsevier in Pharmacological Reviews
- Vol. 71 (2) , 123-156
Modulating Dopamine Signaling and Behavior with Chemogenetics: Concepts, Progress, and Challenges
For more than 60 years, dopamine (DA) has been known as a critical modulatory neurotransmitter regulating locomotion, reward-based motivation, and endocrine functions. Disturbances in DA signaling have been linked to an array of different neurologic and psychiatric disorders, including Parkinson’s disease, schizophrenia, and addiction, but the underlying pathologic mechanisms have never been fully elucidated. One major obstacle limiting interpretation of standard pharmacological and transgenic interventions is the complexity of the DA system, which only appears to widen as research progresses. Nonetheless, development of new genetic tools, such as chemogenetics, has led to an entirely new era for functional studies of neuronal signaling. By exploiting receptors that are engineered to respond selectively to an otherwise inert ligand, so-called Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), chemogenetics enables pharmacological remote control of neuronal activity. Here we review the recent, extensive application of this technique to the DA field and how its use has advanced the study of the DA system and contributed to our general understanding of DA signaling and related behaviors. Moreover, we discuss the challenges and pitfalls associated with the chemogenetic technology, such as the metabolism of the DREADD ligand clozapine N-oxide (CNO) to the D2 receptor antagonist clozapine. We conclude that despite the recent concerns regarding CNO, the chemogenetic toolbox provides an exceptional approach to study neuronal function. The huge potential should promote continued investigations and additional refinements to further expound key mechanisms of DA signaling and circuitries in normal as well as maladaptive behaviors.
- 1 April 2019
- Published by Elsevier in Pharmacological Reviews
- Vol. 71 (2) , 123-156
Modulating Dopamine Signaling and Behavior with Chemogenetics: Concepts, Progress, and Challenges
For more than 60 years, dopamine (DA) has been known as a critical modulatory neurotransmitter regulating locomotion, reward-based motivation, and endocrine functions. Disturbances in DA signaling have been linked to an array of different neurologic and psychiatric disorders, including Parkinson’s disease, schizophrenia, and addiction, but the underlying pathologic mechanisms have never been fully elucidated. One major obstacle limiting interpretation of standard pharmacological and transgenic interventions is the complexity of the DA system, which only appears to widen as research progresses. Nonetheless, development of new genetic tools, such as chemogenetics, has led to an entirely new era for functional studies of neuronal signaling. By exploiting receptors that are engineered to respond selectively to an otherwise inert ligand, so-called Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), chemogenetics enables pharmacological remote control of neuronal activity. Here we review the recent, extensive application of this technique to the DA field and how its use has advanced the study of the DA system and contributed to our general understanding of DA signaling and related behaviors. Moreover, we discuss the challenges and pitfalls associated with the chemogenetic technology, such as the metabolism of the DREADD ligand clozapine N-oxide (CNO) to the D2 receptor antagonist clozapine. We conclude that despite the recent concerns regarding CNO, the chemogenetic toolbox provides an exceptional approach to study neuronal function. The huge potential should promote continued investigations and additional refinements to further expound key mechanisms of DA signaling and circuitries in normal as well as maladaptive behaviors.
- 1 March 2019
- Published by Elsevier in European Journal of Pharmacology
- Vol. 847, 123-129
Differential effects of ADHD medications on impulsive action in the mouse 5-choice serial reaction time task
- 1 March 2019
- Published by Elsevier in European Journal of Pharmacology
- Vol. 847, 123-129
Differential effects of ADHD medications on impulsive action in the mouse 5-choice serial reaction time task
- Open Access
- 31 May 2018
- Published by Society for Neuroscience in eneuro
- Vol. 5 (3)
Locomotor- and Reward-Enhancing Effects of Cocaine Are Differentially Regulated by Chemogenetic Stimulation of Gi-Signaling in Dopaminergic Neurons
Dopamine plays a key role in the cellular and behavioral responses to drugs of abuse, but the implication of metabotropic regulatory input to dopaminergic neurons on acute drug effects and subsequent drug-related behavior remains unclear. Here, we used chemogenetics [Designer Receptors Exclusively Activated by Designer Drugs (DREADDs)] to modulate dopamine signaling and activity before cocaine administration in mice. We show that chemogenetic inhibition of dopaminergic ventral tegmental area (VTA) neurons differentially affects locomotor and reward-related behavioral responses to cocaine. Stimulation of Gi-coupled DREADD (hM4Di) expressed in dopaminergic VTA neurons persistently reduced the locomotor response to repeated cocaine injections. An attenuated locomotor response was seen even when a dual-viral vector approach was used to restrict hM4Di expression to dopaminergic VTA neurons projecting to the nucleus accumbens. Surprisingly, despite the attenuated locomotor response, hM4Di-mediated inhibition of dopaminergic VTA neurons did not prevent cocaine sensitization, and the inhibitory effect of hM4Di-mediated inhibition was eliminated after withdrawal. In the conditioned place-preference paradigm, hM4Di-mediated inhibition did not affect cocaine-induced place preference; however, the extinction period was extended. Also, hM4Di-mediated inhibition had no effect on preference for a sugar-based reward over water but impaired motivation to work for the same reward in a touchscreen-based motivational assay. In addition, to support that VTA dopaminergic neurons operate as regulators of reward motivation toward both sugar and cocaine, our data suggest that repeated cocaine exposure leads to adaptations in the VTA that surmount the ability of Gi-signaling to suppress and regulate VTA dopaminergic neuronal activity.
- 31 May 2018
- Published by Society for Neuroscience in eneuro
- Vol. 5 (3)
Open AccessLocomotor- and Reward-Enhancing Effects of Cocaine Are Differentially Regulated by Chemogenetic Stimulation of Gi-Signaling in Dopaminergic Neurons
Dopamine plays a key role in the cellular and behavioral responses to drugs of abuse, but the implication of metabotropic regulatory input to dopaminergic neurons on acute drug effects and subsequent drug-related behavior remains unclear. Here, we used chemogenetics [Designer Receptors Exclusively Activated by Designer Drugs (DREADDs)] to modulate dopamine signaling and activity before cocaine administration in mice. We show that chemogenetic inhibition of dopaminergic ventral tegmental area (VTA) neurons differentially affects locomotor and reward-related behavioral responses to cocaine. Stimulation of Gi-coupled DREADD (hM4Di) expressed in dopaminergic VTA neurons persistently reduced the locomotor response to repeated cocaine injections. An attenuated locomotor response was seen even when a dual-viral vector approach was used to restrict hM4Di expression to dopaminergic VTA neurons projecting to the nucleus accumbens. Surprisingly, despite the attenuated locomotor response, hM4Di-mediated inhibition of dopaminergic VTA neurons did not prevent cocaine sensitization, and the inhibitory effect of hM4Di-mediated inhibition was eliminated after withdrawal. In the conditioned place-preference paradigm, hM4Di-mediated inhibition did not affect cocaine-induced place preference; however, the extinction period was extended. Also, hM4Di-mediated inhibition had no effect on preference for a sugar-based reward over water but impaired motivation to work for the same reward in a touchscreen-based motivational assay. In addition, to support that VTA dopaminergic neurons operate as regulators of reward motivation toward both sugar and cocaine, our data suggest that repeated cocaine exposure leads to adaptations in the VTA that surmount the ability of Gi-signaling to suppress and regulate VTA dopaminergic neuronal activity.